LIST of ORPHAN PRODUCTS DESIGNATIONS and APPROVALS Throughdecember 31,1999 NAME SPONSOR &

Total Page:16

File Type:pdf, Size:1020Kb

LIST of ORPHAN PRODUCTS DESIGNATIONS and APPROVALS Throughdecember 31,1999 NAME SPONSOR & LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS ThroughDecember 31,1999 NAME SPONSOR &. ADDRESS Generic Name DD=Date Designated TN=Trade Name INDICATION DESIGNATED MA=Marketing Approval 1,S-(Butylimino)- 1,5 Treatment of Fabry’s disease. Oxford GlycoSciences dideoxy,D-glucitol 10, The Quadrant TN= Abington Science Park, Abington Oxfordshire OX14 3YS UK, DD=05/12/1998 MA= I / 1,5-(Butylimino)- 1,5 Treatment of Gaucher disease. Oxford GlycoSciences dideoxy,D-glucitol 10, The Quadrant TN= Abington Science Park, Abington Oxfordshire OX14 3YS UK, DD=05/29/1998 MA= / / 11Hndium pentetreotide Treatment of somatostatinreceptor positive neuroendocrine Louisiana State University Medical Center TN= SomatoTher tumors. Foundation 1600 Canal St. 10th Floor New Orleans, LA 70112 DD=06/10/1999 MA= / / 15AU81 Treatment of pulmonary arterial hypertension. United Therapeutics Corp. TN= 68 T.W. Alexander Dr. P.O. Box 14186 ResearchTriangle Park, NC 27709 DD=06/04/1997 MA= ! 1 166Ho-DOTMP Treatment of multiple myeloma. NeoRx Corporation TN= 4 10 W. Harrison Seattle, WA 98119 DD=02/10/1999 MA= I / 2’-deoxycytidine As a host-protective agent in the treatment of acute Grant, Steven M.D. TN= myelogenous leukemia. Massey Cancer Center, VCU P.O. Box 980230 Richmond, VA 23298 DD=O9/09/1996 MA= ! I 2-0-desulfated heparin Treatment of cystic fibrosis. Kennedy & Hoidal, M.D.‘s TN= Aeropin University of Utah Health SciencesCenter 50 North Medical Drive, Room 4R240 Salt Lake City, UT 84132 DD=09/17/1993 MA= / / 24,25 dihydroxycholecalciferol Treatment of uremic osteodystrophy. Lemrnon Company TN= 1510 Delp Drive Kulpsville, PA 19443 DD=02/27/1987 MA= I I 3:4-diaminopyridine Treatment of Lambert-Eaton myasthenic syndrome. JacobusPharmaceutical Company TN= 37 Cleveland Avenue P.O. Box 5290 Princeton, NJ 08540 DD=12/18/1990 MA= / / Page 1 LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS ThroughDecember 3 1,1999 NAME SPONSOR & ADDRESS Generic Name DD=Date Designated TN=Trade Name INDICATION DESIGNATED MA=varketing Approval 3-(3,5-dimethyl-lH-2ylmethyle Treatment of Kaposi’s sarcoma. Sugen, Inc. ne)- 1,3-dihydro-indol-2-one 230 East Grand Ave. TN= South San Francisco, CA 94080 DD=09/11/1998 MA= / / 4-aminosalicylic acid Treatment of mild to moderateulcerative colitis in patients Beeken, Warren M.D. TN= Pamisyl (P-D), Rezipas intolerant to sulfasalazine. University Of Vermont (Squibb) Given C-3 17 Burlington, VT 05405 DD=I2/13/1989 MA= / / 40SD02 Treatment of chronic iron overload resulting from conventional Biomedical Frontiers, Inc. TN= transfusional treatment of beta-thalassemiamajor and sickle cell 1095 10th Ave., SE. anemia. Minneapolis, MN 55414 DD=12/21/1998 MA= I / 5,6-dihydro-5-azacytidine Treatment of malignant mesothelioma. ILEX Oncology, Inc. TN= 11550 IH 10 West, Suite 300 San Antonio, TX 78230 DD=05/11/1992 MA= / I 5-aza-2’-deoxycytidine Treatment of acute leukemia. PharmachemieU.S.A., Inc. TN= 1510 Delp Dr. Kulpsville, PA 19443 DD=08/03/1987 MA= / 1 506U78 Treatment of chronic lyrnphocytic leukemia. Glaxo Wellcome, Inc. TN= Five Moore Dr. P.O. Box 13398 Durham, NC 27709 DD=09/02/1999 MA= I I 5a8, monoclonal antibody to For use in post-exposureprophylaxis for occupational exposure Biogen, Inc. CD4 to human immunodeficiency virus. 14 Cambridge Center TN= Cambridge, MA 02142 DD=12/20/1993 MA= I f 6-hydroxymethylacylfulvene Treatment of histologically confirmed advancedor metastatic MGI Pharrna, Inc. TN= pancreatic cancer. 6300 West Old ShakoppeRd. Suite 110 Bloomington, MN 55438 DD=04/06/1999 MA= ! / 6-hydroxymethylacylfulvene Treatment of ovarian cancer. MGI Pharrna, Inc. TN= 6300 West Old ShakoppeRd. Suite 110 Bloomington, MN 55438 DD=07/06/1999 MA= I I 6-hydroxymethylacylfulvene Treatment of renal cell carcinoma. MGI Pharma, Inc. TN= 6300 West Old ShakoppeRd. Suite 110 Bloomington, MN 55438 DD=07/27/1999 MA= I I Page 2 LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS ThroughDecember 3 1,1999 NAME SPONSOR & ADDRESS Generic Name DD=Date Designated INDICATION DESIGNATED TN=Trade Name MA=Marketing Approval 8 Cyclopentyl Treatment of cystic fibrosis. SciClone Pharmaceuticals,Inc. 1,3-dipropylxanthine 901 Mariner’s Island Boulevard TN= San Mateo, CA 94404 DD=03/24/1997 MA= I I 8-methoxsalen For use in conjunction with the WAR photopheresisto treat Therakos, Inc. TN= Uvadex diffuse systemic sclerosis. Oaklands Corporate Center 437 Creamery Way Exton, PA 19341 DD=06/22/1993 MA= / / 8-methoxsalen For the prevention of acute rejection of cardiac allografts. Therakos, Inc. TN= Uvadex Oaklands Corporate Center 437 Creamery Way Exton, PA 19341 DD=O5/12/1994 MA= / I 9-cis retinoic acid Treatment of acute promyelocytic leukemia. Ligand Pharmaceuticals,Inc. TN= Panretin 9393 Towne Centre Drive Suite 100 San Diego, CA 92121 DD=04/10/1992 MA= / / 9-nitro-20-(S)-camptothecin Treatment of pancreatic cancer. Stehlin Foundation for Cancer Research TN= 1315 St. JosephParkway, Suite 1818 Houston, TX 77002 DD=O9/16/1996 MA= / I API903 Treatment of acute graft-versus-host diseasein patients Ariad Gene Therapeutics, Inc. TN= undergoing bone marrow transplantation. 26 Landsdowne St. Cambridge, MA 02139 DD=11/24/1999 MA= / / APL 400-020 V-Beta DNA Treatment of cutaneousT cell lymphoma. Wyeth-Lederle Vaccines and Pediatrics vaccine 211 Bailey Rd. TN= West Henrietta, NY 14586 DD=03/08/1995 MA= I / Acetylcysteine Intravenous treatment of patients presenting with moderateto Apothecon TN= MucomystMucomyst 10 severe acetaminophenoverdose. P.O. Box 4500 IV Princeton, NJ 08543 DD=08/13/1987 MA= I I Aconiazide Treatment of tuberculosis. Lincoln Diagnostics TN= P.O. Box 1128 Decatur, IL 62525 DD=06/20/1988 MA= I I Adeno-associatedviral-based Treatment of cystic fibrosis. Targeted Genetics Corporation vector cystic fibrosis gene 1100 Olive Way, Suite 100 therapy Seattle, WA 98101 TN= DD=02/15/1995 MA= / I Page 3 LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS ThroughDecember 3 1,1999 NAME SPONSOR & ADDRESS Generic Name DD=Date Designated TN=Trade Name INDICATION DESIGNATED MA=Marketing Approval Adenovirus-based vector Factor Treatment of hemophilia A. GenStar Therapeutics Corporation VIII complementary DNA to 10835 Altman Row somatic cells Suite 150 TN= MiniAdFVIII San Diego, CA 92121 DD=12/15/1999 MA= I / Albendazole Treatment of hydatid disease(cystic echinococcosisdue to E. SmithKline Beecham Pharmaceuticals TN= Albenza granulosus larvae or alveolar echinococcosisdue to E. One Franklin Plaza multilocularis larvae). P.O. Box 7929 Philadelphia, PA 1910 1 DD=01/17/1996 MA=06/11/1996 Albendazole Treatment of neurocysticercosis due to Taenia solium as: 1) SmithKline Beecham Pharmaceuticals TN= Albenza chemotherapy of parenchymal, subarachnoidal and racemose One Franklin Plaza (cysts in spinal fluid) neurocysticercosis in symptomatic cases P.O. Box 7929 and 2) prophylaxis of epilepsy and other sequelaein Philadelphia, PA 19101 asymptomatic neurocysticercosis. DD=O1/18/1996 MA=0611 111996 Aldesleukin Treatment of primary immunodeficiency diseaseassociated with Chiron Corporation TN= Proleukin T-cell defects. 4560 Horton Street Emeryville, CA 94608 DD=03/22/1989 MA= I / Aldesleukin Treatment of metastatic renal cell carcinoma. Chiron Corporation TN= Proleukin 4560 Horton Street Emeryville, CA 94608 DD=09/14/1988 MA=0510511992 Aldesleukin Treatment of metastaticmelanoma. Chiron Corporation TN= Proleukin 4560 Horton Street Emeryville, CA 94608 DD=09/10/1996 MA=O1/09/1998 Aldesleukin Treatment of acute myelogenous leukemia. Chiron Corporation TN= Proleukin 4560 Horton St. Emeryville, CA 94608 DD=07/31/1998 MA= / I Aldesleukin For the treatment non-Hodgkin’s lyrnphoma. Chiron Corporation TN= Proleukin 4560 Horton St. Emeryville, CA 94608 DD=11/24/1998 MA= I I Alglucerase injection For replacement therapy in patients with Gaucher’sdisease type Genzyme Corporation TN= Ceredase I. One Kendall Square Cambridge, MA 02139 DD=03/11/1985 MA=04/05/1991 Alglucerase injection Replacementtherapy in patients with Type II and III Gaucher’s Genzyme Corporation TN= Ceredase disease. One Kendall Square Cambridge, MA 02 139 DD=07/21/1995 MA= I I Page 4 LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS ThroughDecember 3 1, 1999 NAME SPONSOR & ADDRESS Generic Name DD=Date Designated TN=Trade Name INDICATION DESIGNATED MA=Marketing ., Approval Alitretinoin Topical treatment of cutaneouslesions in patients with Ligand PharmaceuticalsInc. TN= Panretin AIDS-related Kaposi’s sarcoma. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998 MA=02/02/1999 Allogeneic peripheral blood Treatment of pancreatic cancer. Applied Immunotherapeutics, LLC mononuclear cells sensitized 14132 E. Firestone Boulevard against patient alloantigens by Santa Fe Springs, CA 90670 mixed lymphocyte culture DD=OG/13/1997 MA= / I TN= CYTOIMPLANT Allopurinol sodium Management of patients with leukemia, lymphoma, and solid Catalytica Pharmaceuticals,Inc TN= Zyloprim for Injection tumor malignancies who are receiving cancer therapy which PO Box 1887 causeselevations of serum and urinary uric acid levels and who Greenville, NC 27835 cannot tolerate oral therapy. DD=10/16/1992 MA=05/17/1996 Alpha-l -antitrypsin As supplementation therapy for alpha-l-antitrypsin deficiency in Chiron Corporation (recombinant DNA Origin) the ZZ phenotype population. 4560 Horton Street TN= Emeryville, CA 94608 DD=01/01/1984 MA= / / Alpha-galactosidaseA Treatment of Fabry’s disease. Desnick, Robert J. M.D. TN= Fabrase The Mount Sinai School Of Medicine Fifth Avenue at 100th Street, Box 1203 New York, NY 10029 DD=07/20/1990 MA= I I Alpha-galactosidaseA
Recommended publications
  • 1 Therapeutic Antibodies – from Past to Future Stefan Dubel¨ and Janice M
    1 1 Therapeutic Antibodies – from Past to Future Stefan Dubel¨ and Janice M. Reichert 1.1 An Exciting Start – and a Long Trek In the late nineteenth century, the German army doctor Emil von Behring (1854–1917), later the first Nobel Laureate for Medicine, pioneered the thera- peutic application of antibodies. He used blood serum for the treatment of tetanus and diphtheria (‘‘Blutserumtherapie’’). When his data were published in 1890 [1], very little was known about the factors or mechanisms involved in immune defense. Despite this, his smart conclusion was that a human body needs some defense mechanism to fight foreign toxic substances and that these substances should be present in the blood – and therefore can be prepared from serum and used for therapy against toxins or infections. His idea worked, and the success allowed him to found the first ‘‘biotech’’ company devoted to antibody-based therapy in 1904 – using his Nobel Prize money as ‘‘venture capital.’’ The company is still active in the business today as part of CSLBehring. In 1908, Paul Ehrlich, the father of hematology [2] and the first consistent concept of immunology (‘‘lateral chain theory,’’ Figure 1.1d [3]), was awarded the second Nobel Prize related to antibody therapeutics for his groundbreaking work on serum, ‘‘particularly to the valency determination of sera preparations.’’ Ehrlich laid the foundations of antibody generation by performing systematic research on immunization schedules and their efficiency, and he was the first to describe different immunoglobulin subclasses. He also coined the phrases ‘‘passive vaccination’’ and ‘‘active vaccination.’’ His lateral chain theory (‘‘Seitenketten,’’ sometimes misleadingly translated to ‘‘side-chain theory’’) postulated chemical receptors produced by blood cells that fitted intruding toxins (antigens).
    [Show full text]
  • Phage Display-Based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed Against Human Pathogens
    Int. J. Mol. Sci. 2012, 13, 8273-8292; doi:10.3390/ijms13078273 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Phage Display-based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed against Human Pathogens Nicola Clementi *,†, Nicasio Mancini †, Laura Solforosi, Matteo Castelli, Massimo Clementi and Roberto Burioni Microbiology and Virology Unit, “Vita-Salute” San Raffaele University, Milan 20132, Italy; E-Mails: [email protected] (N.M.); [email protected] (L.S.); [email protected] (M.C.); [email protected] (M.C.); [email protected] (R.B.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-2-2643-5082; Fax: +39-2-2643-4288. Received: 16 March 2012; in revised form: 25 June 2012 / Accepted: 27 June 2012 / Published: 4 July 2012 Abstract: In the last two decades, several phage display-selected monoclonal antibodies (mAbs) have been described in the literature and a few of them have managed to reach the clinics. Among these, the anti-respiratory syncytial virus (RSV) Palivizumab, a phage-display optimized mAb, is the only marketed mAb directed against microbial pathogens. Palivizumab is a clear example of the importance of choosing the most appropriate strategy when selecting or optimizing an anti-infectious mAb. From this perspective, the extreme versatility of phage-display technology makes it a useful tool when setting up different strategies for the selection of mAbs directed against human pathogens, especially when their possible clinical use is considered.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 April 2020 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Coun- cil, hereby makes the following regulations. Contents Page 1 Title and commencement 5 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 9 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 April 2020 Part 2 Standards 4 Standards for medicines, related products, medical devices, 10 cosmetics, and surgical dressings 4A Standard for CBD products 10 5 Pharmacist may dilute medicine in particular case 11 6 Colouring substances [Revoked] 11 Part 3 Advertisements 7 Advertisements not to claim official approval 11 8 Advertisements for medicines 11 9 Advertisements for related products 13 10 Advertisements
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Structure, Function, and Therapeutic Use of Igm Antibodies
    antibodies Review Structure, Function, and Therapeutic Use of IgM Antibodies Bruce A. Keyt *, Ramesh Baliga, Angus M. Sinclair, Stephen F. Carroll and Marvin S. Peterson IGM Biosciences Inc, 325 East Middlefield Road, Mountain View, CA 94043, USA; [email protected] (R.B.); [email protected] (A.M.S.); [email protected] (S.F.C.); [email protected] (M.S.P.) * Correspondence: [email protected]; Tel.: +1-650-265-6458 Received: 16 September 2020; Accepted: 9 October 2020; Published: 13 October 2020 Abstract: Natural immunoglobulin M (IgM) antibodies are pentameric or hexameric macro- immunoglobulins and have been highly conserved during evolution. IgMs are initially expressed during B cell ontogeny and are the first antibodies secreted following exposure to foreign antigens. The IgM multimer has either 10 (pentamer) or 12 (hexamer) antigen binding domains consisting of paired µ heavy chains with four constant domains, each with a single variable domain, paired with a corresponding light chain. Although the antigen binding affinities of natural IgM antibodies are typically lower than IgG, their polyvalency allows for high avidity binding and efficient engagement of complement to induce complement-dependent cell lysis. The high avidity of IgM antibodies renders them particularly efficient at binding antigens present at low levels, and non-protein antigens, for example, carbohydrates or lipids present on microbial surfaces. Pentameric IgM antibodies also contain a joining (J) chain that stabilizes the pentameric structure and enables binding to several receptors. One such receptor, the polymeric immunoglobulin receptor (pIgR), is responsible for transcytosis from the vasculature to the mucosal surfaces of the lung and gastrointestinal tract.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]
  • Designated Indication Cumulative List of All Products That Have Received
    Cumulative List of all Products that have received Orphan Designation: Total active designations: 2002 Effecive: 5/5/2009 Generic Name Trade Name Designated Indication treatmentMarketing and/or Approved modification Indication of the Designated Date Market Exculsivity Date following conditions, which are Vaccinia Immune Globulin complications resulting from smallpox (Human) Intravenous CNJ-016 ForTreatment the control of complications and prevention of vacciniaof hemorrhagic vaccination episodes vaccination: Eczema vaccinatum 18.06.2004 01.05.9999 and for surgical prophylaxis in patients with hemophilia Antihemophilic factor A (congenital factor VIII deficiency or classic (recombinant) ReFacto hemophilia). 08.02.1996 01.01.9999 For use as a thyroid blocking agent in For use as a thyroid blocking agent in pediatric patients pediatric patients exposed to Potassium Iodide Oral Solution ThyroShield exposed to radiactive iodine radiactive iodine 17.11.2004 01.01.9999 Treatment (rescue) of respiratory Pulmonary surfactant For the treatment and prevention of respiratory distress distress syndrome in premature replacement, porcine Curosurf syndrome in premature infants. Longinfants. term treatment of children with 02.08.1993 01.01.9999 growth failure due to inadequate Treatment of idiopathic or organic growth hormone secretion of endogenous growth Somatropin (rDNA origin) Saizen deficiency in children with growth failure. Long-termhormone. treatment of growth failure 06.03.1987 01.01.9999 Long-term treatment of children who have growth failure due to a lack of adequate endogenous due to a lack of adequate endogenous growth hormone growth hormone secetion for once- or Somatropin (rDNA origin) Nutropin Depot secretion. twice-a-month administration. 28.10.1999 01.01.9999 Treatment of growth failure in children due to have growth failure due to inadequate Somatropin (rDNA origin) injection Norditropin inadequate growth hormone secretion.
    [Show full text]
  • 1 Supplementary Materials 1 2 Data Sources 3 in Total, 60 Antibodies
    1 Supplementary Materials 2 3 Data Sources 4 In total, 60 antibodies and antibody-based biologics that were approved 5 by the EMA or FDA between 1995 and 2019 were included in our analyses. 6 The excluded antibodies were: (1) the withdrawn or marketing discontinued antibodies 7 or fusion proteins (e.g., muromonab-CD3, efalizumab, tositumomab- 8 I131, daclizumab, catumaxomab, edrecolomab, Nebacumab, and alefacept); (2) 9 antibody-drug conjugates (e.g., brentuximab vedotin, ado-trastuzumab 10 emtansine, inotuzumab ozogamicin, gemtuzumab ozogamicin, 11 and polatuzumab vedotin); (3) bi-specific antibodies (e.g., emicizumab and 12 blinatumomab); (4) antibodies with neither F CL, nor KD information available 13 (e.g., Ibritumomab tiuxetan, efmoroctocog-α, eftrenonacog-α, mogamulizumab, 14 and ustekinumab); (5) single-dosed antibodies that cannot support Css calculation, 15 including abciximab, 16 alemtuzumab, basiliximmab, bezlotoxumab, idarucizumab, obiloxaximab, and 17 raxibacumab; and (6) local dosing and acting antibodies (e.g., aflibercept, ranibizumab, 18 and brolucizumab). 19 We obtained the labeled TDs and dosing regimens from 20 the Drugs@FDA website and the literature. The following information was also 21 collected: (1) molecular weight, (2) administration route, (3) bioavailability (F), (4) in 22 vitro antigen-binding dissociation constant (KD), (5) the antibody systemic clearance 23 (CL), (6) target abundance and half-life, (7) the approved indications, 24 and (8) the mechanism of action. More specifications for these parameters were 25 provided in the Supplementary Table 1. 26 1 27 Supplementary Figure 1 28 29 30 Supplementary Figure 1. Target turnovers are not relevant to TEARs in four 31 disease-target scenarios. Dots represent the mean values.
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]